Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Point-Of-Care Diabetes Test Gains FDA Panel Endorsement As Diagnostic

Executive Summary

Members of US FDA's Clinical Chemistry and Toxicology Device Panel say Alere’s Afinion HbA1c Dx is safe and effective for the diagnosis of diabetes in settings such as larger physician office labs, but were worried about the company’s plan to eventually expand the test’s use to community events.


Related Content

Axis-Shield receives 510(k) clearance for Hba1c test:


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts